Cas:664991-78-0 5-Bromo-2-iodo-4-methyl-3-(3-pyridinyl)-1H-pyrrolo[2,3-b]pyridine manufacturer & supplier

We serve Chemical Name:5-Bromo-2-iodo-4-methyl-3-(3-pyridinyl)-1H-pyrrolo[2,3-b]pyridine CAS:664991-78-0 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

5-Bromo-2-iodo-4-methyl-3-(3-pyridinyl)-1H-pyrrolo[2,3-b]pyridine

Chemical Name:5-Bromo-2-iodo-4-methyl-3-(3-pyridinyl)-1H-pyrrolo[2,3-b]pyridine
CAS.NO:664991-78-0
Synonyms:5-Bromo-2-iodo-4-methyl-3-(3-pyridinyl)-1H-pyrrolo[2,3-b]pyridine
Molecular Formula:C13H9BrIN3
Molecular Weight:414.03900
HS Code:

Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:41.57000
Exact Mass:412.90200
LogP:4.30040

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like 5-Bromo-2-iodo-4-methyl-3-(3-pyridinyl)-1H-pyrrolo[2,3-b]pyridine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,5-Bromo-2-iodo-4-methyl-3-(3-pyridinyl)-1H-pyrrolo[2,3-b]pyridine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,5-Bromo-2-iodo-4-methyl-3-(3-pyridinyl)-1H-pyrrolo[2,3-b]pyridine Use and application,5-Bromo-2-iodo-4-methyl-3-(3-pyridinyl)-1H-pyrrolo[2,3-b]pyridine technical grade,usp/ep/jp grade.


Related News: In the Phase III VICTORIA study, Verquvo met the primary efficacy objective based on a time-to-event analysis. 2,6-bis(3,4,5-trifluorophenyl)-3,3′,5,5′-tetrahydro-4,4′-spirobi[dinaphtho[2,1-c:1′,2′-e]azepin]-4-ium bromide manufacturers SARS-CoV-2 has evolved mutations that severely compromise the neutralizing activities of multiple IgG monoclonal antibodies, including those under clinical trials and authorized for emergency use.
Therefore, developing new antibody therapies that can overcome these challenges is an urgent unmet need, and we are pleased with the data published today,” An said.
“Synergizing the strengths of multiple institutions from academia and industry is the key to the rapid translation from ideas to therapeutic candidates.
This is another example of such success. The cross-institutional and academic-industry collaborations should be expanded to other disease indications,” said Pei-Yong Shi, PhD, professor and co-senior author of the study from the Department of Biochemistry and Molecular Biology at UTMB Health.
This antibody has been licensed to biotech partner IGM Biosciences for drug development.
“The ability to use potently neutralizing IgM antibodies against SARS-CoV-2 with broad coverage of VOCs, VOIs, and viral escape mutants, is a very exciting application of the IGM platform,” said Fred Schwarzer, CEO of IGM Biosciences.
“We are grateful to our collaborators at UTHealth, UTMB Health, and our scientists at IGM for the exceptional work described in Nature today. Naphth[2′,3′:4,5]imidazo[1,2-a]pyridine-6,11-dione, 9-fluoro- suppliers Biocatalysis is widely recognized to be one of the most powerful tools for organic synthesis due to its green credentials and its exquisite regio-, enantio-, and stereoselectivities. 6,10-dimethylundeca-1,5,9-trien-4-ol vendor & factory.